Gene therapy for $1 million? That's so 2018
Remember the good old days of 2018 when we were totally agitated over $1 million gene therapies? How quaint. Like the price of a a cup of coffee in Venezuela, the costs of these one-time curative treatments are skyrocketing overnight.
On Tuesday, Bluebird Bio used its JPM presentation to float the idea of a $2.1 million “intrinsic value” for its Lentiglobin gene therapy to treat patients with a rare, inherited blood disease. Novartis says its gene therapy targeting spinal muscular atrophy could cost $4 million to $5 million.
Neither of these medicines is even approved yet, but they make Luxturna, which for $850,000 can cure a rare form of childhood blindness, look downright cheap. Spark Therapeutics, the maker of Luxturna, might want to rebrand itself as the Dollar Store of gene therapy.
On Tuesday, Bluebird Bio used its JPM presentation to float the idea of a $2.1 million “intrinsic value” for its Lentiglobin gene therapy to treat patients with a rare, inherited blood disease. Novartis says its gene therapy targeting spinal muscular atrophy could cost $4 million to $5 million.
Neither of these medicines is even approved yet, but they make Luxturna, which for $850,000 can cure a rare form of childhood blindness, look downright cheap. Spark Therapeutics, the maker of Luxturna, might want to rebrand itself as the Dollar Store of gene therapy.
.jpeg)
No hay comentarios:
Publicar un comentario